Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Modern Rheumatology
Published in: Modern Rheumatology 5/2012

01-09-2012 | Original Article

Therapeutic response of patients with adult Still’s disease to biologic agents: multicenter results in Japan

Authors: Rie Suematsu, Akihide Ohta, Emi Matsuura, Hiroki Takahashi, Takao Fujii, Takahiko Horiuchi, Seiji Minota, Yoshiaki Ishigatsubo, Toshiyuki Ota, Shuji Takei, Sachiko Soejima, Hisako Inoue, Syuichi Koarada, Yoshifumi Tada, Kohei Nagasawa

Published in: Modern Rheumatology | Issue 5/2012

Login to get access

Abstract

Objective

The efficacy of biologics in treating adult Still’s disease (ASD) is suggested, but the information is still lacking and the validation is insufficient. To determine the efficacy of several biologic agents in refractory ASD in Japan, a multicenter survey was performed.

Method

Clinical data on 16 ASD patients who had been treated with at least 1 of the biological agents (total 24 occasions) were collected retrospectively.

Results

Infliximab was used in 9 cases, etanercept in 4, and tocilizumab in 11. Half of the patients that had been treated initially with infliximab or etanercept were changed to another biologics. Tocilizumab was effective in cases switched from another 2 drugs. Tocilizumab showed efficacy in treating both systemic and arthritic symptoms and showed apparent steroid-sparing effect and the highest continuation rate.

Conclusion

Tocilizumab may be a promising biologic agent in refractory ASD.
Literature
1.
Efthimou P, Paik PK, Bielory L. Diagnosis and management of adult onset Still’s disease. Ann Rheum Dis. 2006;65:564–72.CrossRef
2.
Ohta A, Yamaguchi M, Tsunematsu T, Kasukawa R, Mizushima H, Kashiwagi H, et al. Adult Still’s disease: a multicenter survey of Japanese patients. J Rheumatol. 1990;17:1058–63.PubMed
3.
Choi J-H, Suh C-H, Lee Y-M, Suh Y-J, Lee S-K, Kim S-S, et al. Serum cytokine profiles in patients with adult onset Still’s disease. J Rheumatol. 2003;30:2422–7.PubMed
4.
Chen D-Y, Lan J-L, Lin F-J, Hsieh T-Y. Proinflamatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still’s disease. J Rheumatol. 2004;31:2189–98.PubMed
5.
Hoshino T, Ohta A, Yang D, Kawamoto M, Kikuchi M, Inoue Y, et al. Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still’s disease. J Rheumatol. 1998;25:396–8.PubMed
6.
Efthimiou P, Georgy S. Pathogenesis and management of adult-onset Still’s disease. Semin Arthritis Rheum. 2006;36:144–52.PubMedCrossRef
7.
Franchini S, Dagna L, Salvo F, Aiello P, Baldissera E, Sabbadini MG. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still’s disease. Arthritis Rheum. 2010;62:2530–5.PubMedCrossRef
8.
Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still’s disease. Arthritis Rheum. 2005;52:1794–803.PubMedCrossRef
9.
Fautrel B, Sibilia J, Mariette X, Combe B; Club Rheumatismes et Inflammation. Tumour necrosis factor alpha blocking agents in refractory adult Still’s disease: an observational study of 20 cases. Ann Rheum Dis. 2005;64:262–6.PubMedCrossRef
10.
Cavagna L, Caporali R, Epis O, Bobbio-Pallavini F, Montecucco C. Infliximab in the treatment of adult Still’s disease refractory to conventional therapy. Clin Exp Rheumatol. 2001;19:329–32.PubMed
11.
Kraetsch HG, Antoni C, Kalden JR, Manger B. Successful treatment of a small cohort of patients with adult onset of Still’s disease with infliximab: first experiences. Ann Rheum Dis. 2001;60[Suppl 3]:iii55–7.PubMed
12.
Kokkinos A, Iliopoulos A, Greka P, et al. Successful treatment of refractory adult-onset Still’s disease with infliximab. A prospective, non-comparative series of four patients. Clin Rheumatol. 2004;23:45–9.PubMedCrossRef
13.
Tamesis ER, Reginato AM, Hubscher O, Reginato AJ. Etanercept in recalcitrant adult onset Still’s disease. Arthritis Rheum. 2000;43:S229.
14.
Husni ME, Maier AL, Mease PJ, Overman SS, Fraser P, Garvallese EM, et al. Etanercept in the treatment of adult patients with Still’s disease. Arthritis Rheum. 2002;46:1171–6.PubMedCrossRef
15.
Naumann L, Feist E, Natusch A, Langen S, Krause A, Buttgereit F, et al. IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still’s disease. Ann Rheum Dis. 2010;69:466–7.PubMedCrossRef
16.
Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:961–3.CrossRef
17.
Iwamoto M, Nara H, Hirata D, Minota S, Nishimoto N, Yoshizaki K. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still’s disease. Arthritis Rheum. 2002;46:3388–9.PubMedCrossRef
18.
De Bandt M, Saint-Marcoux B. Tocilizumab for multirefractory adult-onset Still’s disease. Ann Rheum Dis. 2009;68:153–4.PubMedCrossRef
19.
Kishida D, Okuda Y, Onishi M, Takebayashi M, Matoba K, Joutama K, et al. Successful tocilizumab treatment in patient with adult-onset Still’s disease complicated by chronic active hepatitis B and amyloid A amyloidisis. Mod Rheumatol. 2011;21:215–8.PubMedCrossRef
20.
Matsumoto K, Nagashima T, Takatori S, Kawahara Y, Yagi M, Iwamoto M, et al. Glucocorticoid and cyclosporine refractory adult onset Still’s disease successfully treated with tocilizumab. Cin Rheumatol. 2009;28:485–7.CrossRef
21.
Nakahara H, Mima T, Yoshio-Hoshino N, Matsushita M, Hashimoto J, Nishimoto N. A case report of patient with refractory adult-onset Still’s disease who was successfully treated with tocilizumab over 6 years. Mod Rheumatol. 2009;19:69–72.PubMedCrossRef
22.
Sumida K, Ubara Y, Hoshino J, Suwabe T, Hiramatsu R, Hasegawa E, et al. Etanercept-refractory adult-onset Still’s disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab. Clin Rheumatol. 2010;29:1191–4.PubMedCrossRef
23.
Naniwa T, Ito R, Watanabe M, Hayami Y, Maeda S, Sasaki K, et al. Successful use of short-term add-on tocilizumab for multirefractory systemic flare of adult-onset Still’s disease. Clin Rheumatol. 2010. [Epub ahead of print].
24.
Sabnis GR, Gokhale YA, Kulkarni UP. Tocilizumab in refractory adult-onset Still’s disease with aseptic meningitis-efficacy of interleoukin-6 blockade and review of the literature. Semin Arthritis Rheum. 2011;40:365–8.PubMedCrossRef
25.
Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19:424–30.PubMed
26.
van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Güler-Yüksel M, Zwinderman AH, Kerstens PJ, et al. Drug-free remission, and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis. 2009;68:914–21.PubMedCrossRef
27.
Maruyama J, Inokuma S. Cytokine profiles of macrophage activation syndrome associated with rheumatic disease. J Rheumatol. 2010;37:967–73.PubMedCrossRef
28.
Arlet JB, Le TH, Marinho A, Amoura Z, Wechsler B, Papo T, et al. Reactive haemophagocytic syndrome in adult-onset Still’s disease: a report of six patients and review of the literature. Ann Rheum Dis. 2006;65:1596–601.PubMedCrossRef
29.
Mitamura M, Tada Y, Koarada S, Inoue H, Suematsu R, Ohta A, et al. Cyclosporin A treatment for Japanese patients with severe adult-onset Still’s disease. Mod Rheumatol. 2009;19:57–63.PubMedCrossRef
30.
Kaneko K, Kaburaki M, Muraoka S, Tanaka N, Yamamoto T, Kusunoki Y, et al. Exacerbation of adult-onset Still’s disease, possibly related to elevation of serum tumor necrosis factor-alpha after etanercept administration. Int J Rheum Dis. 2010;13:e67–9.PubMedCrossRef
31.
Gianella S, Schaer DJ, Schwarz U, Kurrer M, Heppner FL, Fehr J, Seebach JD. Retinal microangiopathy and rapidly fatal cerebral edema in patient with adult-onset Still’s disease and concurrent macrophage activation syndrome. Am J Hematol. 2008;83:424–7.PubMedCrossRef
32.
Stern A, Riley R, Buckley L. Worsening of macrophage activation syndrome in a patient with adult onset Still’s disease after initiation of etanercept therapy. J Clin Rheumatol. 2001;7:252–6.PubMedCrossRef
33.
Kobayashi M, Takahashi Y, Yamashita H, Kaneko H, Mimori A. Benefit and a possible risk of tocilizumab therapy for adult-onset Still’s disease accompanied by macrophage-activation syndrome. Mod Rheumatol. 2011;21:92–6.PubMedCrossRef
34.
Puéchal X, DeBandt M, Berthelot JM, Mreban M, Dubost JJ, Fain O, et al. Tocilizumab in refractory adult Still’s disease. Arthritis Care Res. 2011;63:155–9.CrossRef
Metadata
Title
Therapeutic response of patients with adult Still’s disease to biologic agents: multicenter results in Japan
Authors
Rie Suematsu
Akihide Ohta
Emi Matsuura
Hiroki Takahashi
Takao Fujii
Takahiko Horiuchi
Seiji Minota
Yoshiaki Ishigatsubo
Toshiyuki Ota
Shuji Takei
Sachiko Soejima
Hisako Inoue
Syuichi Koarada
Yoshifumi Tada
Kohei Nagasawa
Publication date
01-09-2012
Publisher
Springer Japan
Published in
Modern Rheumatology / Issue 5/2012
Print ISSN: 1439-7595
Electronic ISSN: 1439-7609
DOI
https://doi.org/10.1007/s10165-011-0569-6

Other articles of this Issue 5/2012

Modern Rheumatology 5/2012 Go to the issue

Case Report

Cutaneous polyarteritis nodosa associated with HLA-B39-positive undifferentiated spondyloarthritis in a Japanese patient

Review Article

Current strategies for microRNA research

Case Report

Good response to infliximab in a patient with deep vein thrombosis associated with Behçet disease

Original Article

Whole-body fluorodeoxyglucose positron emission tomography/computed tomography in patients with active polymyalgia rheumatica: evidence for distinctive bursitis and large-vessel vasculitis

Letter

The new model of sick building syndrome

Letter

The new model of sick building syndrome: inclusion in ASIA or Shoenfeld’s syndrome
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits